Is Family Care overvalued or undervalued?

As of 24 October 2025, the valuation grade for Family Care has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios reveal a PE ratio of 0.82, an EV to EBITDA of 0.98, and an ROE of 219.63%, which, while impressive, are overshadowed by the high valuation relative to peers.
In comparison, Max Healthcare is categorized as very expensive with a PE ratio of 95.69, while Apollo Hospitals is rated attractive with a PE of 71.66. These comparisons suggest that Family Care's valuation does not align favorably with its peers, despite its strong operational metrics. Furthermore, the company's stock has significantly underperformed against the Sensex, with a year-to-date return of -32.88% compared to the Sensex's 7.77%, reinforcing the notion that Family Care is currently overvalued.